LUYE PHARMA GROUP LTD. 綠葉製藥集團有限公司 （於 百 慕 達 註 冊 成 立 之 有 限 公 司） （股 份 代 號：02186） 委任提名委員會成員 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 之全部或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何 責 任。 承董事會命 綠葉製藥集團有限公司 主 席 劉殿波 香 港，2025年12月31日 於 本 公 告 日 期，本 公 司 執 行 董 事 為 劉 殿 波 先 生、楊 榮 兵 先 生、袁 會 先 先 生 及 祝 媛 媛 女 士；本 公 司 非 執 行 董 事 為 宋 瑞 霖 先 生 及 黃 立 明 先 生；及 本 公 司 獨 立 非 執 行 董 事 為 張 化 橋 先 生、盧 毓 琳 教 授、梁 民 傑 先 生、蔡 思 聰 先 生 及 夏 蓮 女 士。 綠葉製藥集團 有限公司（「本公司」）董事會（「董事會」）謹 此 宣 佈，本 公 司 獨 立 非 執行董事夏蓮女士已獲委任為本公 ...

LUYE PHARMA GROUP LTD. 綠葉製藥集團有限公司 （於 百 慕 達 註 冊 成 立 之 有 限 公 司） （股 份 代 號：02186） 獨立非執行董事 張化橋先生 盧毓琳教授 梁民傑先生 蔡思聰先生 夏蓮女士 董事名單及其角色與職能 綠葉製藥集團有限公司 董 事 會 成 員 載 列 如 下： 執行董事 劉殿波先生 （執 行 主 席 及 首 席 執 行 官） 楊榮兵先生 （執 行 副 主 席） 袁會先先生 祝媛媛女士 非執行董事 宋瑞霖先生 C 相關董事委員會主席 M 相關董事委員會成員 香 港 2025年12月31日 黃立明先生 本 公 司 設 有 四 個 董 事 委 員 會。該 等 委 員 會 的 成 員 資 料 載 列 如 下： | 董事委員會 | | | | 環 境、 | | --- | --- | --- | --- | --- | | | | | | 社會及管治 | | 董事 | 審核委員會 | 薪酬委員會 | 提名委員會 | 委員會 | | 楊榮兵先生 | | | | M | | 宋瑞霖先生 | | | | M | | 張化橋先生 | M | M | M | | | 盧毓琳教授 ...

Core Viewpoint - Recently, Green Leaf Pharmaceutical announced a significant transaction involving the transfer of 25% equity in Nanjing Green Leaf to Nanjing Xinshi for a total consideration of RMB 1,086,383,600 [1][9][10]. Group 1: Equity Transfer Agreement - The equity transfer agreement was dated December 25, 2025, with the withdrawing investor as the transferor and Nanjing Xinshi as the transferee [1][9]. - The transfer price includes RMB 1,000 million as the purchase price for the 25% equity, plus interest calculated at an annual rate of 6% from the purchase date until the settlement date [10]. Group 2: Payment Structure - The payment for the equity transfer will be made in three installments: 1. 25% within five business days after the fulfillment of transaction conditions, no later than December 31, 2025 2. 25% by January 16, 2026 3. The remaining balance within ten business days after the completion of the equity transfer registration [2][10]. Group 3: Completion Conditions - The completion of the equity transfer is contingent upon several conditions, including amendments to Nanjing Green Leaf's articles of association, completion of filing with the Asset Management Association of China, obtaining all necessary internal, regulatory, and third-party approvals, and ensuring no significant adverse changes at the time of completion [2][10]. Group 4: Financial Performance - Nanjing Green Leaf is projected to maintain a net profit exceeding RMB 400 million in 2024 [4][12].

Investment Rating - The report indicates a cautious outlook on the pharmaceutical industry, with the overall investment rating reflecting a mixed performance in the sector [2][3]. Core Insights - The Shenwan Pharmaceutical and Biological Index decreased by 0.2% this week, while the Shanghai Composite Index rose by 1.88%, ranking the pharmaceutical index 25th among 31 Shenwan sub-industries [2][3]. - The current valuation of the pharmaceutical sector stands at 29.2 times earnings, placing it 10th among 31 Shenwan primary industries [5]. - Recent collaborations in the industry include significant licensing agreements, such as the partnership between JAKOS and AstraZeneca for the Pan-KRAS inhibitor, which could yield up to $20.15 billion in potential payments [11]. - The report highlights the ongoing challenges in the industry, including a decline in the number of retail pharmacies, which has seen a net reduction of over 8,800 stores in the last quarter alone [16]. Market Performance - The pharmaceutical sector's performance this week showed a decline of 0.2%, with various sub-sectors experiencing mixed results, such as raw materials (+2.0%) and hospitals (-2.8%) [2][5]. - The report notes that the pharmaceutical index's performance is lagging compared to other sectors, indicating a need for strategic adjustments [3][5]. Recent Developments - The sixth batch of national procurement for medical consumables has been officially launched, which may impact pricing and availability in the market [14]. - Several innovative drugs and medical devices have received approval for market entry, including Novo Nordisk's oral semaglutide, marking a significant advancement in obesity treatment [19][21]. - The report also mentions the IPO applications of several companies, including Xinnowei and Frontera, indicating a trend of new entrants seeking capital in the pharmaceutical sector [26][29].

Group 1 - Green Leaf Pharmaceutical (02186.HK) announced a share transfer agreement involving Nanjing Green Leaf, a subsidiary, where an investor will transfer 25% of its stake for RMB 1.086 billion to Nanjing Xinshi [1] - Nanjing Xinshi is a limited partnership, with Shandong Green Leaf, a wholly-owned subsidiary, acquiring approximately 33.2% of its partnership interests for RMB 200 million [1] - The remaining interests in Nanjing Xinshi are held by China Cinda (approximately 66.4%) and two general partners, Hangzhou Xinshi and Yantai Hexin, each holding about 0.2% [1] Group 2 - Nanjing Xinshi has the right to request Yantai Green Leaf to repurchase its stake in Nanjing Green Leaf under a share option agreement upon the occurrence of specified events [2] - Yantai Green Leaf has the option to require China Cinda to sell its interests in Nanjing Xinshi, and must also acquire Hangzhou Xinshi's partnership interests if it exercises this option [2] - Following the completion of the share transfer, Nanjing Xinshi will secure bank financing of up to RMB 648 million, with Yantai Green Leaf and Shenzhen Green Leaf providing guarantees for this financing [2]

Group 1 - Green Leaf Pharmaceutical (02186) announced a share transfer agreement involving Nanjing Green Leaf, a subsidiary, where an investor will transfer 25% of its stake for RMB 1.086 billion to Nanjing Xinshi [1] - Nanjing Xinshi, a limited partnership, will acquire the stake, while Shandong Green Leaf, a wholly-owned subsidiary, subscribed to approximately 33.2% of Nanjing Xinshi's partnership interests for RMB 200 million [1] - The remaining interests in Nanjing Xinshi are held by China Cinda with about 66.4% and by Hangzhou Xinshi and Yantai Hexin as general partners, each holding approximately 0.2% [1] Group 2 - Following the share transfer, Nanjing Xinshi is expected to secure bank financing of up to RMB 648 million, with guarantees provided by Yantai Green Leaf and Shenzhen Green Leaf [2] - The purpose of the transaction is to introduce third-party investors to provide financing and support for the payment of the share transfer, ensuring timely access to necessary funds for acquiring the 25% stake in Nanjing Green Leaf [2] - Nanjing Green Leaf and its subsidiaries primarily engage in the production and sale of pharmaceuticals, focusing on cancer treatment [2]

Core Viewpoint - Green Leaf Pharmaceutical (02186) announced a share transfer agreement involving its subsidiary, Nanjing Green Leaf, where an investor will transfer 25% of its equity to Nanjing Xinshi for RMB 1.086 billion, aimed at securing financing and support for the company’s operations in the oncology sector [1][2]. Group 1: Share Transfer Agreement - The investor, Shenzhen Green Leaf Private Equity Investment Fund, will transfer 25% of its stake in Nanjing Green Leaf to Nanjing Xinshi for RMB 1.086 billion [1]. - Nanjing Xinshi, a limited partnership, will hold approximately 33.2% of the partnership interests after a previous investment of RMB 200 million by Shandong Green Leaf [1]. - The remaining interests in Nanjing Xinshi are held by China Cinda (66.4%) and other partners [1]. Group 2: Financing and Obligations - Following the share transfer, Nanjing Xinshi is expected to secure bank financing of up to RMB 648 million, with guarantees provided by Shandong Green Leaf and Shenzhen Green Leaf [2]. - Nanjing Xinshi is required to make semi-annual distributions to China Cinda as per the partnership agreement [2]. - The agreements include options for Shandong Green Leaf to acquire interests from China Cinda and other partners under specified conditions [2]. Group 3: Business Focus - Nanjing Green Leaf and its subsidiaries primarily engage in the production and sale of pharmaceuticals, focusing on oncology treatments [2].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 之全部或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何 責 任。 LUYE PHARMA GROUP LTD. 綠葉製藥集團有限公司 （於 百 慕 達 註 冊 成 立 之 有 限 公 司） （股 份 代 號：02186） 須予披露交易 轉讓南京綠葉25%權益及關聯交易 轉讓南京綠葉25%權益及關聯交易 於2025年12月25日，南 京 綠 葉、撤 資 投 資 者 及 南 京 信 石 訂 立 股 權 轉 讓 協 議， 據 此，撤 資 投 資 者 同 意 以 人 民 幣1,086,383,600元向南京信石轉讓其於南京綠 葉25%的 股 權。南 京 信 石 為 一 家 有 限 合 夥 企 業。於2025年10月，山 東 綠 葉 作 為 有限合夥人根據合夥協議以人民幣200百萬元認購南京信石約33.2%合夥權 益。南 京 信 石 的 餘 下 權 益 由 中 國 信 達 作 為 另 一 名 有 限 合 夥 人 持 有 ...

这三款产品分别为瑞可妥、瑞百莱和美比瑞，均适用于精神分裂症的治疗。恩华和信将负责以上产品在 中国大陆的独家经销与商业化，公司则继续持有该三款产品的资产权、注册证及全部知识产权等权利， 并负责产品的生产和供货。协议期限为10年，恩华将一次性支付公司不可退还的2000万美元授权费。 近日，绿叶制药发布公告，公司与恩华药业（002262）的附属公司江苏恩华和信医药营销有限公司签署 合作协议，授予恩华和信三款抗精神病药长效针剂产品在中国大陆地区的独家商业化权利。 ...

Company News - Bank of China (03988.HK) has completed the issuance of 50 billion yuan in subordinated capital bonds, with the funds intended to supplement the bank's Tier 2 capital, subject to applicable laws and regulatory approvals [2] - Huadian International Power (01071.HK) has fully commissioned two 660,000 kW ultra-supercritical units at the Huadian Longkou Phase IV project, which integrates advanced technologies and achieves energy consumption levels comparable to the best in the domestic market, enhancing grid stability and local heating and industrial steam supply [2] - Weisheng Holdings (03393.HK) has entered into a capital increase agreement with Boyu Capital, with Boyu investing a total of 380 million yuan to subscribe for additional shares in its subsidiary [3] - Green Leaf Pharmaceutical (02186.HK) has granted Enhua exclusive commercialization rights for three long-acting injectable antipsychotic products in mainland China [4] - Heng Rui Medicine (01276.HK) has had its injectable SHR-A1904 included in the list of breakthrough therapy products by the drug review center [5] - Youzhiyou Biotechnology-B (02496.HK) has received IND approval from NMPA for Y225 (Aimeisai monoclonal antibody injection) [6] - MicroPort Robotics-B (02252.HK) has achieved a global commercialization milestone with over 100 installations of its Tumi laparoscopic surgical robot [7] - Gao Shan Enterprises (00616.HK) has signed a memorandum of understanding to establish a joint venture to participate in or invest in stablecoins and blockchain-related industries [8] - Energy International Investment (00353.HK) plans to issue a total of 1.035 billion subscription shares at a discount of approximately 18.33%, aiming to raise about 254 million HKD [9] Buyback Activities - Tencent Holdings (00700.HK) has repurchased approximately 636 million HKD worth of 1.056 million shares at prices ranging from 598 to 604 HKD [10] - Xiaomi Group-W (01810.HK) has spent 149 million HKD to repurchase 3.8 million shares at prices between 39.08 and 39.26 HKD [11] - China COSCO Shipping Holdings (01919.HK) has repurchased shares worth approximately 27.225 million HKD, acquiring 1.96 million shares at prices from 13.82 to 13.95 HKD [12] - Kuaishou-W (01024.HK) has repurchased shares for about 29.9896 million HKD, buying 464,000 shares at prices between 64.05 and 64.9 HKD [13]